Nature Communications 2015-01-01

Injectable cryogel-based whole-cell cancer vaccines.

Sidi A Bencherif, R Warren Sands, Omar A Ali, Weiwei A Li, Sarah A Lewin, Thomas M Braschler, Ting-Yu Shih, Catia S Verbeke, Deen Bhatta, Glenn Dranoff, David J Mooney

Index: Nat. Commun. 6 , 7556, (2015)

Full Text: HTML

Abstract

A biomaterial-based vaccination system that uses minimal extracorporeal manipulation could provide in situ enhancement of dendritic cell (DC) numbers, a physical space where DCs interface with transplanted tumour cells, and an immunogenic context. Here we encapsulate GM-CSF, serving as a DC enhancement factor, and CpG ODN, serving as a DC activating factor, into sponge-like macroporous cryogels. These cryogels are injected subcutaneously into mice to localize transplanted tumour cells and deliver immunomodulatory factors in a controlled spatio-temporal manner. These vaccines elicit local infiltrates composed of conventional and plasmacytoid DCs, with the subsequent induction of potent, durable and specific anti-tumour T-cell responses in a melanoma model. These cryogels can be delivered in a minimally invasive manner, bypass the need for genetic modification of transplanted cancer cells and provide sustained release of immunomodulators. Altogether, these findings indicate the potential for cryogels to serve as a platform for cancer cell vaccinations.